Association of Drug Effects on Serum Parathyroid Hormone, Phosphorus, and Calcium Levels With Mortality in CKD: A Meta-analysis  by Palmer, Suetonia C. et al.
Original InvestigationFrom th
Christchurc
University
ScientiﬁcOf
School of M
5CORE: Cen
Pescara; 6D
Nephrology
Eastern Pie
Organ Tran
Received
30, 2015. O
962Association of Drug Effects on Serum Parathyroid Hormone,
Phosphorus, and Calcium Levels With Mortality in CKD:
A Meta-analysis
Suetonia C. Palmer, MBChB, PhD,1 Armando Teixeira-Pinto, PhD,2
Valeria Saglimbene, MSc,3 Jonathan C. Craig, MBChB, PhD,2 Petra Macaskill, PhD,2
Marcello Tonelli, MD,4 Giorgia de Berardis, MSc,5 Marinella Ruospo, MSc,3,6 and
Giovanni F.M. Strippoli, MD, PhD2,3,7
Background: Serum parathyroid hormone (PTH), phosphorus, and calcium levels are surrogate outcomes
that are central to the evaluation of drug treatments in chronic kidney disease (CKD). This systematic review
evaluates the evidence for the correlation between drug effects on biochemical (PTH, phosphorus, and cal-
cium) and all-cause and cardiovascular mortality end points in adults with CKD.
Study Design: Systematic review and meta-analysis.
Setting & Population: Adults with CKD.
Selection Criteria for Studies: Randomized trials reporting drug effects on biochemical and mortality end
points.
Intervention: Drug interventions with effects on serum PTH, phosphorus, and calcium levels, including
vitamin D compounds, phosphate binders, cinacalcet, bisphosphonates, and calcitonin.
Outcomes: Correlation between drug effects on biochemical and all-cause and cardiovascular mortality.
Results: 28 studies (6,999 participants) reported both biochemical and mortality outcomes and were eligible
for analysis. Associations between drug effects on surrogate biochemical end points and corresponding effects
on mortality were weak and imprecise. All correlation coefficients were less than 0.70, and 95% credible
intervals were generally wide and overlapped with zero, consistent with the possibility of no association. The
exception was an inverse correlation between drug effects on serum PTH levels and all-cause mortality, which
was nominally significant (20.64; 95% credible interval, 20.85 to 20.15), but the strength of this association
was very imprecise. Risk of bias within available trials was generally high, further reducing confidence in the
summary correlations. Findings were robust to adjustment for age, baseline serum PTH level, allocation
concealment, CKD stage, and drug class.
Limitations: Low power in analyses and combining evidence from many different drug comparisons with
incomplete data across studies.
Conclusions: Drug effects on serum PTH, phosphorus, and calcium levels are weakly and imprecisely
correlated with all-cause and cardiovascular death in the setting of CKD. Risks of mortality (patient-level
outcome) cannot be inferred from treatment-induced changes in biochemical outcomes in people with CKD.
Similarly, existing data do not exclude a mortality benefit with treatment. Trials need to address patient-
centered outcomes to evaluate drug effectiveness in this setting.
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Drug Effects on Biochemical and Mortality OutcomesTreatment of chronic kidney disease (CKD) or itscomplications commonly involves modifying
biological end points (such as urine protein excretion
or blood pressure) with the ultimate aim of improving
patient-relevant outcomes, such as survival or delay-
ing end-stage kidney disease.1 Biological markers
have also been used widely as primary outcomes for
the evaluation of drug efﬁcacy and to accelerate
regulatory approvals based on the assumption that
treatment effects on these end points lead to improved
outcomes that are relevant to patients.2-4 Surrogate
end points are frequently used in research and clinical
practice because they are more sensitive to drug ef-
fects, occur more quickly than patient-level outcomes,
and are easier to measure, reducing the complexity
and duration of research and treatment. However, for
a surrogate end point to be clinically meaningful,
treatment effects on surrogate outcomes (such as
albuminuria) need to reliably predict effects on true
end points of clinical value (such as cardiovascular
events). Changes in glomerular ﬁltration rate as an
end point in clinical trials in CKD have received
speciﬁc attention from the US Food and Drug
Administration recently.5
The bone disease that complicates CKD (known as
CKD2mineral and bone disorder [CKD-MBD]) is one
large-scale example of this practice in which correcting
surrogate end points (abnormal serum parathyroid
hormone [PTH], phosphorus, and calcium levels) is
standard clinical practice in the belief that this reduces
mortality and morbidity.6 These biochemical end
points have also been used for the purpose of regulatory
approvals and the publicly funded subsidy of drugs,
including phosphate binders and vitamin D com-
pounds.7,8 The prescribing of vitamin D compounds,
phosphate binders, and calcimimetic agents to correct
serum phosphorus and PTH levels in CKD is ubiqui-
tous in routine clinical practice and suggested by global
guidelines.6 In 2010, the calcimimetic agent cinacalcet
was the single most costly drug prescribed for US
dialysis patients based on its ability to lower serum
PTH levels.9 Despite the extensive prescribing of
these drugs and associated medication costs, there is
uncertainty about their effects on cardiovascular and
all-cause mortality.10,11
We have previously examined the association be-
tween serum PTH, phosphorus, and calcium levels
and all-cause mortality in cohort studies and found no
robust evidence of a strong and consistent associa-
tion.12 However, an evaluation of the link between
drug effects on these surrogate biochemical end
points and patient-centered outcomes in clinical trials
is absent. This study evaluates the assumption that
drug effects on widely used surrogate end points
(serum PTH, phosphorus, or calcium levels) in men
and women with CKD are correlated with drug effectsAm J Kidney Dis. 2015;66(6):962-971on total and cardiovascular mortality within random-
ized trials.
METHODS
We conducted this systematic review according to the Preferred
Reporting Items for Systematic Reviews and Meta-analyses
(PRISMA) statement.13
Data Sources and Searches
We searched existing meta-analyses published in the Cochrane
Library for trials reporting interventions for CKD-MBD.14-18 We
supplemented data from existing meta-analyses by searching the
Cochrane Central Register of Controlled Trials (CENTRAL)
through issue 12, 2014, and MEDLINE (through January week
3, 2015) for study reports using highly sensitive search strategies
designed by an information specialist without language restriction.
We used the search strategies available in the original Cochrane
review publications and supplemented these with a speciﬁc strat-
egy for trials targeting speciﬁc biochemical values of serum PTH,
phosphorus, and calcium (Table S1, available as online supple-
mentary material).
Study Selection
We considered randomized studies in any language comparing
any intervention for CKD-MBD or kidney transplantation2related
bone disease, including phosphate binders, vitamin D compounds,
calcimimetic agents, bisphosphonates, and calcitonin, to evaluate
any association between drug effects on biochemical end points
(serum PTH, phosphorus, or calcium) and drug effects on mortality
outcomes. Inclusion criteria were the availability of reported serum
PTH, phosphorus, or calcium levels at the end of follow-up or the
proportion of participants achieving a speciﬁed biochemical target
level in all treatment arms together with reporting of one or more
mortality event during follow-up. We excluded data about children
and from trials in which follow-up was shorter than 12 weeks.
Data Extraction and Quality Assessment
We deﬁned the biochemical outcomes of interest a priori
as either the end-of-treatment serum biochemical value (PTH,
phosphorus, or calcium) or the proportion achieving a prespeciﬁed
target range by end of treatment. The mortality outcomes of
interest were all-cause and cardiovascular mortality. Data
were extracted by one reviewer (V.S.) and double-checked by a
second reviewer (G.d.B.). Any disagreements were resolved by
discussion.
To avoid double-counting of participants in studies that evalu-
ated a single drug intervention in 2 or more arms (eg, several doses
of a single drug in 3 different study arms), we combined event data
for the binary outcomes (mortality and biochemical) for all inter-
vention arms of the same drug into a single analysis or extracted
data from the highest dose treatment arm for continuous outcomes
(end-of-treatment biochemical values). Risk of bias was adjudi-
cated using standard tools generated by the Cochrane Collabora-
tion, including the domains of sequence generation, allocation
concealment, blinding of participants or investigators, blinding of
outcome assessment, and completeness of outcome data.19 We
also identiﬁed reports of sponsor involvement in authorship and/or
data analysis or management.19
Data Synthesis and Analysis
For each study, the log ratio of mean biochemical values or the
log relative proportion of the study population in each arm
achieving a prespeciﬁed serum target value at the end of treatment
for the intervention and control arms were computed together with
the respective standard errors. For all studies, the log relative risk963
Palmer et alof all-cause and/or cardiovascular mortality was also calculated
and the standard error was derived.
We then generated scatterplots of the effect on mortality (rela-
tive risk) on the vertical axis and the effect on biochemical
outcome (ratio of means for serum biochemical values at end of
treatment) on the horizontal axis. The area of the point estimate
was proportional to the sample size and contribution of the study
to the overall correlation coefﬁcient. In these plots, point estimates
indicating beneﬁts for both outcomes (lower end-of-treatment
biochemical value and lower mortality with treatment) were seen
in the lower left quadrant. We also generated plots of the effect on
mortality on the vertical axis and the effect on achieving the
biochemical target (relative risk) on the horizontal axis. In these
plots, point estimates indicating beneﬁts for both outcomes (higher
likelihood of the biochemical target and lower mortality with
treatment) were seen in the lower right-hand quadrant.
The association between treatment effects on surrogate end
points and mortality outcomes was then quantiﬁed using bivariate
random-effects meta-analysis. Because the within-study correla-
tion between treatment effects on biochemical and mortality end
points was not available in individual studies, we used the
approach proposed by Riley et al20 that combined the between-
and within-study correlations into a single parameter. This corre-
lation was estimated assuming a bivariate normal distribution for
the relative risk of mortality and the drug effect on the corre-
sponding biochemical outcome (either the ratio of the mean end-
of-treatment serum biochemical level or the relative risk of
achieving the prespeciﬁed biochemical target range). Although a
single regression line showing the correlation between drug effects
on biochemical end points and mortality would have aided inter-
pretation of the ﬁndings, the 2 components of the correlation
(between-study and within-study) were inseparable and therefore
plotting such a regression line in the scatterplots was not possible.
The model was ﬁtted using a Bayesian approach with uninfor-
mative normal—N(0, 1,000)—priors for the means’ parameters,
uninformative uniform—U(0, 10,000)—priors for the variance
components, and an uninformative uniform—U(21, 1)—prior for
the correlation. Four Markov chain Monte Carlo chains of 100,000
iterations each were used to compute the posterior distributions,
after 10,000 burn-in iterations. We used Gelman and Rubin21 di-
agnostics and inspection of trace plots to check for convergence of
Markov chain Monte Carlo chains.
We then explored several covariates (mean age, baseline serum
PTH level, allocation concealment, CKD stage, and drug class) as
sources of heterogeneity in the estimated correlations. Separate
bivariate normal models, including each one of the covariates of
interest as a linear effect, were ﬁtted to investigate the impact of
the covariate on the estimated correlations. For analysis of co-
variate effects, we also assumed uninformative normal priors.
A 95% credible interval was calculated for all correlations. The
Bayesian 95% credible interval is interpreted as having a 95%
probability of including the true correlation between surrogate and
clinical end points. For an overview of Bayesian methods, we
suggest Bland and Altman.22 An interval that excluded zero
indicated a statistically signiﬁcant correlation between treatment
effects on biochemical and mortality outcomes. All statistical an-
alyses were conducted with R statistical software, version 3.1.1
(R Foundation for Statistical Computing), using the JAGS (“Just
Another Gibbs Sampler”) package (http://mcmc-jags.sourceforge.
net/).
RESULTS
Description of Included Studies
We identiﬁed 756 citations from electronic searches
and 148 studies in previous systematic reviews (Fig 1).964There were 32 studies involving 6,999 participants
that met our inclusion criteria (Table S2).2,23-53 The
sources of funding in the included studies are reported
in Table S3.
Overall, 30 trials reported all-cause mortality data
and 13 reported cardiovascular mortality data. No
study prespeciﬁed analysis of the association of drug
effects on intermediary biochemical end points with
subsequent mortality outcomes. The median event rate
for mortality was 3.0 (range, 0-26.2) per 100 patients
and cardiovascular death was 0.1 (range, 0-5.1) per
100 patients, which were 10- to 20-fold lower than
median event rates for achieving biochemical targets
(PTH, 40.8 [range, 5.1-90.1]; calcium, 61.8 [range,
12.5-94.8]; and phosphorus, 53.4 [range, 36.6-82.8]
per 100 patients). Trials had generally small sample
sizes with a median of 40 (range, 6-1,053) patients in
each treatment arm. Publication date range was 1981
to 2014.
Seven interventions could be evaluated: phosphate
binders (3,154 participants), cinacalcet (1,737 partic-
ipants), vitamin D compounds (537 participants),
bisphosphonates (121 participants), calcitonin (16
participants), placebo (1,007 participants), or standard
care (727 participants). Eight studies involved par-
ticipants with stages 1 to 5 CKD, 21 studies involved
participants treated with dialysis, and 3 involved
kidney transplant recipients. Average study follow-up
was 9.9 6 8.1 (standard deviation) months. The target
serum biochemical end points in the contributing tri-
als are described in Table S4.
Risks of Bias
Most studies did not report procedures for sequence
generation or allocation concealment (Figs 2 and S1).
Sixteen (50%) were double blind. None reported
blinded outcome assessment, and withdrawal of
randomly assigned participants from analyses was
.10% and/or imbalanced between groups in 18 (56%)
studies. Fifteen (47%) reported sponsor involvement
in authorship and/or data management.
Effect Sizes for Surrogate Outcomes and Death
In 30 studies (6,580 participants), the range of the
point estimates for the relative risk of mortality was
0.11 to 5.21, and in 13 studies (4,223 participants),
point estimates for relative risk of cardiovascular death
were similarly variable (range, 0.14-3.00). Overall,
statistically signiﬁcant effects were seen in 1 of 30 (3%)
studies for all-cause mortality and none of the studies
reporting data for cardiovascular death. For drug ef-
fects on prespeciﬁed serum biochemical targets, point
estimate ranges were 1.07 to 10.37 for PTH, 0.31 to
61.49 for calcium, and 0.7 to 1.6 for phosphorus. Sta-
tistically signiﬁcant effects were seen in 9 of 13 (69%)
studies for PTH, 3 of 7 studies (43%) for calcium, andAm J Kidney Dis. 2015;66(6):962-971
Figure 1. PRISMA flow diagram for identification of included studies.
Drug Effects on Biochemical and Mortality Outcomesall but 1 of 7 studies (86%) reporting treatment effects
on phosphorus. Point estimates for effects of drugs on
serum biochemical values at end of treatment varied
from 2522 to 207 pg/mL for PTH with statistical sig-
niﬁcance in 13 of 18 studies (72%),21.0 to 0.7 mg/dL
for calcium with signiﬁcant effects in 9 of 21 studiesFigure 2. Risk of bias graph: review authors’ judgments about e
standard domains are reported according to criteria established by th
numbers of trials adjudicated as low, unclear, or high risk of bias for
Am J Kidney Dis. 2015;66(6):962-971(43%), and 21.25 to 0.96 mg/dL for phosphorus with
statistical signiﬁcance in 8 of 22 studies (36%).
Correlations of Effect Sizes
Scatterplots indicated variable and inconsistent asso-
ciations between treatment effects on achieving targetach risk of bias domains in included studies. The risks of bias in
e Cochrane Collaboration. The numbers within the bars show the
each domain.
965
Figure 3. Study-level assessment of the association between relative drug effects on achievement of a target biochemical value
(serum parathyroid hormone [PTH], phosphorus, and calcium) and mortality (all-cause and cardiovascular) outcomes. Each point rep-
resents the association between the relative drug effect on achieving a prespecified serum biochemical target value (horizontal axis)
and the relative risk of all-cause or cardiovascular mortality (vertical axis) within a single study. A point estimate indicating a relative
beneficial effect of the active intervention compared to another treatment, placebo, or standard care (lower mortality and achievement
of biochemical target range) would be seen in the lower right quadrant. The colors represent different drugs as active treatment
(calcimimetic 5 red; phosphate binder 5 blue; vitamin D 5 green). The area of each point is proportional to the sample size of the
contributing study. The Bayesian correlation of the effects of drug treatment on biochemical and mortality end points estimated using
bivariate metaregression is shown together with the 95% credible interval. A 95% credible interval that includes zero is consistent with
no statistical evidence of correlation.
Palmer et albiochemical outcomes and mortality (Fig 3) and
mean end-of-treatment biochemical levels and mortality
(Fig 4). Bivariate modeling conﬁrmed this visual inter-
pretation, ﬁnding weak and nonsigniﬁcant correlations966between surrogate and clinical end points across the
range of outcome combinations. Correlations between
effect sizes for biochemical and mortality outcomes were
all less than 0.70, and the 95% credible intervals for allAm J Kidney Dis. 2015;66(6):962-971
Figure 4. Study-level assessment of the association between relative drug effects on biochemical end points as continuous out-
comes (serum parathyroid hormone [PTH], phosphorus, and calcium) and mortality (all-cause and cardiovascular) outcomes. Each
point represents the association between the relative drug effects on serum biochemical end points as the ratio of mean end of treat-
ment serum value between the treatment groups (horizontal axis) and the relative risk of all-cause or cardiovascular mortality (vertical
axis) within a single study. A point estimate indicating a relative beneficial effect of the active intervention compared to another treat-
ment, placebo, or standard care (lower mortality and lower serum biochemical value with treatment) would be seen in the lower left
quadrant. The colors represent different drugs as active treatment (bisphosphonate 5 yellow; calcimimetic 5 red; phosphate
binder 5 blue; vitamin D 5 green). The area of each point is proportional to the sample size of the contributing study. The Bayesian
correlation of the effects of drug treatment on biochemical and mortality end points estimated using bivariate meta-regression is shown
together with the 95% credible interval. A 95% credible interval that includes zero is consistent with no statistical evidence of
correlation.
Drug Effects on Biochemical and Mortality Outcomescorrelation coefﬁcients overlapped with zero, consistent
with evidence of no correlation. The exception was a
signiﬁcant but imprecise inverse correlation between
mean drug effects on serum PTH level and all-causeAm J Kidney Dis. 2015;66(6):962-971mortality (correlation coefﬁcient, 20.64; 95% credible
interval, 20.85 to 20.15), suggesting with considerable
uncertainty that a higher serumPTHvalue following drug
treatment correlated with lower total mortality.967
Palmer et alAdjustment for Covariates
Findings were similar whenwe adjusted correlations
between biochemical end points and all-cause mortal-
ity for key covariates including age, stage of kidney
disease, drug used, studymethodology, and serumPTH
level (Table S5). In adjusted analyses, correlation co-
efﬁcients remained less than 0.70 (or20.70) with 95%
credible intervals that included the possibility of no
correlation. The exception was the inverse association
between serum PTH levels and all-cause mortality,
which remained statistically signiﬁcant yet imprecise
when analyses were adjusted for baseline serum PTH
level, CKD stage, and some drug treatments
(bisphosphonate or calcimimetic agent).
We examined correlations between biochemical
end points and mortality outcomes separately in
studies involving participants treated with dialysis and
those with CKD (Figs S2 and S3). Results for par-
ticipants treated with dialysis were largely similar to
the main analyses. Data were considerably sparser for
those with earlier stages of CKD and robust conclu-
sions could not be drawn.
DISCUSSION
We found that the effects of a broad range of drugs
used widely in CKD to correct perturbed serum PTH,
phosphorus, and calcium levels generally do not
correlate with cardiovascular and all-cause mortality
in randomized trials, although the effects of these
drugs in standard clinical practice are universally
measured based on improvements in levels of such
biomarkers. Although most studies showed large ef-
fects on PTH, calcium, and phosphorus levels, drug
effects on mortality outcomes were much smaller and
generally not statistically signiﬁcant. Few available
studies reported both surrogate and clinical end points
sufﬁciently to be included in analysis. Biochemical
end points were at best weakly correlated with mor-
tality and the only statistically signiﬁcant association
observed between serum PTH levels and death was
very imprecise. Findings were similar when adjusted
for age, severity of kidney disease, study quality,
serum PTH level, and drug class. These ﬁndings
suggest there is little evidence that the effects of drug
treatment on biochemical markers for bone disease
provide reliable information about cardiovascular
mortality or death in people with CKD, which has
important implications for trial design, regulatory
approval, and clinical practice.
Biochemical end points such as serum calcium and
phosphorus levels are plausible end points for drug
efﬁcacy in clinical trials because of their putative
mechanistic contributions to vascular calciﬁcation and
injury.54 However, this study showing weak or no
correlations between drug effects on biochemical end968points and mortality outcomes together with our
previous study showing a generally poor evidentiary
basis for associations between these biochemical
markers and patient-level outcomes in cohort studies
suggests these markers are unsuitable as indicators of
drug efﬁcacy.12 Elsewhere in CKD, well-known ex-
amples of frank discordance between proposed
beneﬁcial drug effects on a biochemical outcome and
mortality (eg, erythropoiesis-stimulating agents in-
crease hemoglobin levels but also increase mortal-
ity)55 suggest caution is needed before accepting
biochemical outcomes as relevant to drug research.
Validated surrogate markers of treatment effect and
safety are few in clinical practice and research.56
This meta-analysis highlights the possibility that
mortality, although a critical outcome for drug effects
and safety in CKD, might not be the optimal patient-
relevant outcome in randomized trials in this clinical
setting. Despite mortality rates of 10% to 20% per
year for patients treated with dialysis, all-cause and
cardiovascular deaths were uncommon in studies in
this review and drug treatment had no demonstrable
effect. This might be because the studies had rela-
tively small sample sizes (median, 40 participants)
and because of their brevity (,11 months), which
yielded low statistical power. Alternatively, although
it is implied that drug effects on biochemical out-
comes such as phosphorus and PTH levels modify
clinically relevant outcomes in CKD because of their
assumed role in the causal pathways of vascular
calciﬁcation and injury, the pathologic mechanisms
causing death in these patients are poorly understood.
It is possible that these drugs have no tangible effects
on relevant biological pathways leading to health
outcomes, although they appear to favorably modify
intermediate biochemical markers and vascular
calciﬁcation.57 In addition, drugs for bone disease
may only partially modify some pathophysiologic
pathways causing cardiovascular disease that are
mediated through the biochemical outcomes under
study, but fail to modify other competing causes of
death or morbidity that are equally biologically rele-
vant, and lead to a null overall drug effect. On the
basis of these ﬁndings, the central role of surrogate
biochemical markers of bone disease in the drug
management of CKD appears to be of uncertain
clinical value.
Treatment of abnormal serum PTH and phosphorus
levels in CKD may have other beneﬁcial effects that
have not been adequately addressed in existing ran-
domized trials.10,11,14 The condition CKD-MBD is
also associated with hospitalization, itch, fracture,
bone pain, muscle weakness, impaired physical
function, and health-related quality of life, which are
all relevant outcomes for clinical research.58 Because
patients with CKD highly value developing betterAm J Kidney Dis. 2015;66(6):962-971
Drug Effects on Biochemical and Mortality Outcomesdrugs to reduce complications from bone disease,59,60
such “nonmortality” outcomes represent appropriate
and potentially high-signal end points for future drug
trials that need to be considered in study design and
regulatory approvals of new agents.11,14,15,18
Several actively recruiting drug trials report PTH
levels or other biological measures such as coronary
artery calciﬁcation as primary outcomes for evaluating
efﬁcacy (ClinicalTrials.gov study numbers
NCT01020487, NCT01672047, NCT01651000,
NCT01382212, NCT01785875, NCT01447368, and
NCT01696279), suggesting that biochemical end points
remain as key outcomes in clinical trials in CKD,
perpetuating the problems of using potentially unproven
biochemical end points in drug evaluation. Although
many of these trials are small and in the evaluative stage
of newer medicines, routine capture of patient-centered
outcomes such as hospitalization and quality of life
and other symptoms within these trials systematically
might, when analyzed cumulatively in the future,
enhance our understanding of the place of bone disease
treatment in clinical practice beyond biochemical end
points.
This study has limitations that need to be considered
when interpreting the ﬁndings. Despite a systematic
search of Cochrane databases, the data on which these
analyses are based included few mortality outcomes in
trials that were generally of short duration (,11
months), leading to low power in meta-analyses. A
beneﬁcial effect of altering biochemical outcomes
cannot be excluded. This review evaluated correlations
between biomarkers and clinical end points but did not
directly address whether early drug-induced changes in
serum biochemical values could lower subsequent
mortality because data were not available. Formal
validation of surrogate end points including PTH,
phosphorus, and calcium levels (showing that the
treatment’s effect on a surrogate end point dependably
predicts the effect on the true end point) would require
individual patient data from trials that have shown large
effect sizes for the outcome relevant to patients under
study, and which are not currently available. Finally,
the trials in this review had key methodological limi-
tations, particularly due to participant attrition and
nonblinding of outcome assessment, that reduced our
conﬁdence in the conclusions drawn from contributing
data. Trials were generally of insufﬁcient duration to
determine whether biochemical outcomes might
translate into mortality beneﬁts.
In conclusion, drug effects on serum PTH, phos-
phorus, and calcium levels are weakly and imprecisely
correlated with mortality in CKD at best. Inferring that
the beneﬁts of drug effects on biochemical end points
translate into improved patient-level health outcomes is
not possible based on existing evidence. Future trials of
drugs for CKD-MBD need to measure outcomes thatAm J Kidney Dis. 2015;66(6):962-971are relevant to patients, such as pain, itch, physical
function, and muscle weakness, while proxies of all-
cause or cardiovascular mortality within such trials
need to be properly validated if they are to be relevant to
clinical practice and drug evaluation.
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